Single-cell sequencing reveals clonal heterogeneity in acute lymphoblastic leukemia
See our latest video: "What If "
https://www.youtube.com/watch?v=5syCq1ObCvc --~--
"This webinar outlines a project that performs large-scale and integrative single-cell technology genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse. ALL is the most common cancer in children and shows extensive genetic intra-tumoral heterogeneity. This heterogeneity may be the underlying reason for an incomplete response to treatment and the development of relapse. Data from this study provides information about the sensitivity of each leukemia clone to therapy and about how relapse can develop. Moreover, the results point toward the feasibility of detecting minor clinically relevant leukemia clones at diagnosis or during the early days of treatment in ALL.
The main focus of this webinar is:
- Introduction of the Tapestri Platform from Mission Bio for targeted single-cell DNA sequencing
- Presentation of a novel custom panel covering the 300 most mutated genomic regions in ALL
- Insights into the clonal architecture of pediatric T-ALL, lessons learned from the first 16 samples processed with this custom ALL panel"
Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industryโs first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas include oncology blood cancers, solid tumors, and genome editing validation to name a few.
Learn more about Mission Bio: https://missionbio.com/
LinkedIn: https://www.linkedin.com/company/mission-bio/
Twitter: https://twitter.com/missionbio
Facebook: https://www.facebook.com/missionbio
Subscribe to our emails and updates: https://go.missionbio.com/l/55....2252/2020-06-26/bhq5
No comments found